Inogen (NASDAQ:INGN) Raised to “Hold” at StockNews.com

Inogen (NASDAQ:INGN) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Several other equities research analysts have also commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research note on Wednesday, May 8th. Stifel Nicolaus boosted their price objective on shares of Inogen from $6.00 to $7.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Inogen presently has an average rating of “Hold” and an average target price of $7.00.

Inogen Stock Down 2.5 %

Shares of INGN traded down $0.20 during trading hours on Monday, reaching $7.95. 149,849 shares of the company traded hands, compared to its average volume of 447,346. The company’s fifty day moving average price is $7.89 and its two-hundred day moving average price is $7.23. The company has a market capitalization of $187.46 million, a price-to-earnings ratio of -1.92 and a beta of 1.07. Inogen has a 12 month low of $4.13 and a 12 month high of $11.98.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, May 7th. The medical technology company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.14. Inogen had a negative net margin of 30.07% and a negative return on equity of 42.87%. The business had revenue of $78.03 million for the quarter, compared to analyst estimates of $73.67 million. During the same quarter in the previous year, the firm posted ($0.63) earnings per share. Inogen’s quarterly revenue was up 8.1% on a year-over-year basis. On average, analysts expect that Inogen will post -2.43 EPS for the current year.

Insider Transactions at Inogen

In other news, EVP Jason Somer sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $8.56, for a total transaction of $85,600.00. Following the completion of the transaction, the executive vice president now directly owns 4,452 shares of the company’s stock, valued at $38,109.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.99% of the company’s stock.

Institutional Trading of Inogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Price T Rowe Associates Inc. MD boosted its position in shares of Inogen by 5.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company’s stock worth $193,000 after purchasing an additional 1,188 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Inogen by 84.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 2,419 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Inogen by 27.8% during the fourth quarter. SG Americas Securities LLC now owns 12,782 shares of the medical technology company’s stock worth $70,000 after acquiring an additional 2,782 shares during the last quarter. Strs Ohio boosted its position in shares of Inogen by 9.0% during the fourth quarter. Strs Ohio now owns 41,300 shares of the medical technology company’s stock worth $226,000 after acquiring an additional 3,400 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of Inogen by 2,918.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 7,646 shares during the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.